These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 35331501)

  • 21. Efficacy of romosozumab in patients with osteoporosis on maintenance hemodialysis in Japan; an observational study.
    Sato M; Inaba M; Yamada S; Emoto M; Ohno Y; Tsujimoto Y
    J Bone Miner Metab; 2021 Nov; 39(6):1082-1090. PubMed ID: 34324082
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of combined calcium and vitamin D supplementation on osteoporosis in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials.
    Liu C; Kuang X; Li K; Guo X; Deng Q; Li D
    Food Funct; 2020 Dec; 11(12):10817-10827. PubMed ID: 33237064
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study.
    McClung MR; Brown JP; Diez-Perez A; Resch H; Caminis J; Meisner P; Bolognese MA; Goemaere S; Bone HG; Zanchetta JR; Maddox J; Bray S; Grauer A
    J Bone Miner Res; 2018 Aug; 33(8):1397-1406. PubMed ID: 29694685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab.
    McClung MR; Bolognese MA; Brown JP; Reginster JY; Langdahl BL; Maddox J; Shi Y; Rojeski M; Meisner PD; Grauer A
    Osteoporos Int; 2020 Nov; 31(11):2231-2241. PubMed ID: 32623487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonresponder Considerations for Romosozumab Treatment.
    Tominaga A; Wada K; Okazaki K; Nishi H; Terayama Y; Shimamoto S; Kodama Y; Kato Y
    Calcif Tissue Int; 2023 Aug; 113(2):157-165. PubMed ID: 37138124
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Romosozumab added to ongoing denosumab in postmenopausal osteoporosis, a prospective observational study.
    Adami G; Pedrollo E; Rossini M; Fassio A; Braga V; Pasetto E; Pollastri F; Benini C; Viapiana O; Gatti D
    JBMR Plus; 2024 Apr; 8(4):ziae016. PubMed ID: 38544922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
    J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
    Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Further significant effects of eldecalcitol on bone resorption markers and bone mineral density in postmenopausal osteoporosis patients having undergone long-term bisphosphonate treatment.
    Iba K; Sonoda T; Takada J; Dohke T; Yamashita T
    J Bone Miner Metab; 2017 Mar; 35(2):171-176. PubMed ID: 26832388
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of isolated vitamin D supplementation on bone turnover markers in younger postmenopausal women: a randomized, double-blind, placebo-controlled trial.
    Nahas-Neto J; Cangussu LM; Orsatti CL; Bueloni-Dias FN; Poloni PF; Schmitt EB; Nahas EAP
    Osteoporos Int; 2018 May; 29(5):1125-1133. PubMed ID: 29450585
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A systematic review and meta-analysis of efficacy and safety of Romosozumab in postmenopausal osteoporosis.
    Singh S; Dutta S; Khasbage S; Kumar T; Sachin J; Sharma J; Varthya SB
    Osteoporos Int; 2022 Jan; 33(1):1-12. PubMed ID: 34432115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
    Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab.
    Kendler DL; Bone HG; Massari F; Gielen E; Palacios S; Maddox J; Yan C; Yue S; Dinavahi RV; Libanati C; Grauer A
    Osteoporos Int; 2019 Dec; 30(12):2437-2448. PubMed ID: 31628490
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials.
    Hernandez AV; Pérez-López FR; Piscoya A; Pasupuleti V; Roman YM; Thota P; Herrera A
    Maturitas; 2019 Nov; 129():12-22. PubMed ID: 31547908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vitamin D and Calcium Are Required during Denosumab Treatment in Osteoporosis with Rheumatoid Arthritis.
    Nakamura Y; Suzuki T; Yoshida T; Yamazaki H; Kato H
    Nutrients; 2017 Apr; 9(5):. PubMed ID: 28445420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of romosozumab among Japanese postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease.
    Miyauchi A; Hamaya E; Nishi K; Tolman C; Shimauchi J
    J Bone Miner Metab; 2022 Jul; 40(4):677-687. PubMed ID: 35639174
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clodronic acid in the treatment of postmenopausal osteoporosis.
    Tanakol R; Yarman S; Bayraktaroglu T; Boztepe H; Alagöl F
    Clin Drug Investig; 2007; 27(6):419-33. PubMed ID: 17506592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of high-dose vitamin D on bone mineral density and bone turnover markers in postmenopausal women with low bone mass--a randomized controlled 1-year trial.
    Grimnes G; Joakimsen R; Figenschau Y; Torjesen PA; Almås B; Jorde R
    Osteoporos Int; 2012 Jan; 23(1):201-11. PubMed ID: 21909730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial.
    Langdahl BL; Libanati C; Crittenden DB; Bolognese MA; Brown JP; Daizadeh NS; Dokoupilova E; Engelke K; Finkelstein JS; Genant HK; Goemaere S; Hyldstrup L; Jodar-Gimeno E; Keaveny TM; Kendler D; Lakatos P; Maddox J; Malouf J; Massari FE; Molina JF; Ulla MR; Grauer A
    Lancet; 2017 Sep; 390(10102):1585-1594. PubMed ID: 28755782
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis.
    Roux C; Binkley N; Boonen S; Kiel DP; Ralston SH; Reginster JY; Pong A; Rosenberg E; Santora A;
    Calcif Tissue Int; 2014 Feb; 94(2):153-7. PubMed ID: 23912950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.